OverviewSuggest Edit

NuCana is a clinical-stage biopharmaceutical company developing new medicines to treat cancer. It offers ProTide technology, specific combinations of aryl, ester, and amino acid groups (phosphoramidate motifs) that protect the activated nucleotide analog. The ProTide candidates include Acelarin, NUC-3373, and NUC-7738.
TypePublic
Founded2008
HQEdinburgh, GB
Websitenucana.com

Latest Updates

Employees (est.) (Dec 2020)29
Share Price (Sept 2021)$2.4(-5%)
Cybersecurity ratingBMore

Key People/Management at NuCana

Hugh Griffith

Hugh Griffith

Founder, CEO & Board Member
Don Munoz

Don Munoz

Chief Financial Officer
Jeffrey Bloss

Jeffrey Bloss

Chief Medical Officer
Theresa Bruce

Theresa Bruce

Senior VP Clinical Operations
Gordon Kennovin

Gordon Kennovin

VP CMC & Development
Elisabeth Oelmann

Elisabeth Oelmann

Senior VP Medical & Clinical Development
Show more

NuCana Office Locations

NuCana has offices in Edinburgh, London and Newton
Edinburgh, GB (HQ)
3 Lochside Way
London, GB
77 Cannon St
Newton, MA, US
Riverside Center, 275 Grove St, Auburndale
Show all (3)

NuCana Financials and Metrics

NuCana Revenue

GBP

Net income (FY, 2018)

(13.8m)

EBITDA (FY, 2018)

(18.8m)

EBIT (FY, 2018)

(19.1m)

Market capitalization (14-Sept-2021)

123.6m

Closing stock price (14-Sept-2021)

2.4

Cash (31-Dec-2018)

77.0m
NuCana's current market capitalization is $123.6 m.
GBPFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Operating expense total

3.8m6.9m9.0m

EBITDA

(6.9m)(8.3m)(25.5m)(18.8m)

EBIT

(6.9m)(8.4m)(25.7m)(19.1m)

Pre tax profit

(3.7m)(6.5m)(8.2m)(25.5m)(18.1m)
GBPFY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

2.02.02.02.02.02.02.02.0117.1k3.2k759.2k1.0m6.4m4.9m36.4m29.2m20.0m86.7m77.0m

Accounts Receivable

42.3k17.3k185.8k385.2k561.8k511.7k639.5k148.8k21.0k67.0k165.0k

Inventories

365.7k

Current Assets

2.02.02.02.02.02.02.02.0159.4k386.1k945.0k1.4m6.9m5.4m37.1m30.7m25.8m94.0m83.6m
GBPFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(3.1m)(5.3m)(6.0m)(23.1m)(13.8m)

Depreciation and Amortization

43.5k101.0k

Accounts Payable

133.1k220.0k

Cash From Operating Activities

(2.6m)(4.5m)(9.3m)(8.7m)(12.2m)
GBPFY, 1999

Financial Leverage

1 x
Show all financial metrics

NuCana Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

NuCana Online and Social Media Presence

Embed Graph

NuCana News and Updates

NuCana Announces Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary Tract Cancer Study

Enrollment of 418 Evaluable Patients Expected to Enable First Interim Analysis in the First Half of 2022

NuCana Reports Second Quarter 2021 Financial Results and Provides Business Update

EDINBURGH, United Kingdom, Aug. 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2021 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer

Seasoned Physician-Executive Further Strengthens Leadership Team Seasoned Physician-Executive Further Strengthens Leadership Team

NuCana to Present at the Jefferies Virtual Healthcare Conference

EDINBURGH, United Kingdom, May 25, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference being held from June 1…

NuCana to Participate in the 7th Annual Truist Securities Life Sciences Summit

EDINBURGH, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at the 7th Annual Truist Securities Life Sciences Summit being held virtually f…

NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 9 to 14, 2021. Data from all three of NuCana’s ProTides in clinic…
Show more

NuCana Frequently Asked Questions

  • When was NuCana founded?

    NuCana was founded in 2008.

  • Who are NuCana key executives?

    NuCana's key executives are Hugh Griffith, Don Munoz and Jeffrey Bloss.

  • How many employees does NuCana have?

    NuCana has 29 employees.

  • Who are NuCana competitors?

    Competitors of NuCana include Italfarmaco, Achilles Therapeutics and Chugai Pharmaceutical.

  • Where is NuCana headquarters?

    NuCana headquarters is located at 3 Lochside Way, Edinburgh.

  • Where are NuCana offices?

    NuCana has offices in Edinburgh, London and Newton.

  • How many offices does NuCana have?

    NuCana has 3 offices.